Literature DB >> 16800158

Simulating the real world of antihyperglycaemic therapies in type 2 diabetes.

Amanda I Adler1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16800158     DOI： 10.2165/00019053-200624001-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  14 in total

1.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.

Authors:  I M Stratton; A I Adler; H A Neil; D R Matthews; S E Manley; C A Cull; D Hadden; R C Turner; R R Holman
Journal:  BMJ       Date:  2000-08-12

2.  National Institute for Clinical Excellence and its value judgments.

Authors:  Michael D Rawlins; Anthony J Culyer
Journal:  BMJ       Date:  2004-07-24

Review 3.  Guidelines for computer modeling of diabetes and its complications.

Authors: 
Journal:  Diabetes Care       Date:  2004-09       Impact factor: 19.112

4.  Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial.

Authors:  M A Chaudhary; S C Stearns
Journal:  Stat Med       Date:  1996-07-15       Impact factor: 2.373

5.  Trends and influences on use of antidiabetic drugs in England, 1992-2003.

Authors:  Tom Walley; Dyfrig Hughes; Helen Kendall
Journal:  Pharmacoepidemiol Drug Saf       Date:  2005-11       Impact factor: 2.890

6.  Effect of improved glycemic control on health care costs and utilization.

Authors:  E H Wagner; N Sandhu; K M Newton; D K McCulloch; S D Ramsey; L C Grothaus
Journal:  JAMA       Date:  2001-01-10       Impact factor: 56.272

7.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

8.  A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes.

Authors:  Giancarlo Viberti; Steven E Kahn; Douglas A Greene; William H Herman; Bernard Zinman; Rury R Holman; Steven M Haffner; Daniel Levy; John M Lachin; Rhona A Berry; Mark A Heise; Nigel P Jones; Martin I Freed
Journal:  Diabetes Care       Date:  2002-10       Impact factor: 19.112

9.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial.

Authors:  Carlos Abraira; William Duckworth; Madeline McCarren; Nicholas Emanuele; Danielle Arca; Domenic Reda; William Henderson
Journal:  J Diabetes Complications       Date:  2003 Nov-Dec       Impact factor: 2.852
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.